Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial | Zendy

Aristides K Maniatis | Zendy; Ulhas M Nadgir | Zendy; Paul Saenger | Zendy; Kent Reifschneider | Zendy; Jennifer Abuzzahab | Zendy; Larry C. Deeb | Zendy; Larry A. Fox | Zendy; Katie A. Woods | Zendy; Wenjie Song | Zendy; Meng Mao | Zendy; Steven Chessler | Zendy; Allison Komirenko | Zendy; Aimee D Shu | Zendy; Samuel J. Casella | Zendy; Paul Thornton | Zendy

Open Access

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial

Author(s) -

Aristides K Maniatis,

Ulhas M Nadgir,

Paul Saenger,

Kent Reifschneider,

Jennifer Abuzzahab,

Larry C. Deeb,

Larry A. Fox,

Katie A. Woods,

Wenjie Song,

Meng Mao,

Steven Chessler,

Allison Komirenko,

Aimee D Shu,

Samuel J. Casella,

Paul Thornton

Publication year - 2022

Publication title -

hormone research in paediatrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.816

H-Index - 89

eISSN - 1663-2826

pISSN - 1663-2818

DOI - 10.1159/000524003

Subject(s) - tolerability , somatropin , medicine , adverse effect , growth hormone deficiency , pediatrics , growth hormone , hormone

The phase 3 fliGHt Trial evaluated the safety and tolerability of once-weekly lonapegsomatropin, a long-acting prodrug, in children with growth hormone deficiency (GHD) who switched from daily somatropin therapy to lonapegsomatropin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore